Skip to main content

Table 2 Drug Compliance (N = 52)

From: A single-arm, phase 2 study of adjuvant chemotherapy with oral tegafur-uracil for pathologically lymphovascular invasion positive stage IA non-small cell lung cancer: LOGIK0602 study

Discontinuation Day No. of Patients Completion Rate (%) Reason for Discontinuation
  52 100  
5 51 98.1 Grade 1 anorexia (Patient refusal)
5 50 96.2 Grade 2 malaise (Patient refusal)
42 49 94.2 Recurrence
47 48 92.3 Grade 1 diarrhea (Patient refusal)
134 47 90.4 Grade 3 elevation of AST or ALT
141 46 88.5 Grade 3 elevation of total bilirubin
171 45 86.5 Patient refusal
217 44 84.6 Patient refusal
245 43 82.7 Grade 3 body weight loss
267 42 80.8 Grade 2 elevation of AST or ALT
311 41 78.8 Grade 3 malaise
321 40 76.9 Grade 2 dry skin
403 39 75.0 Grade 2 nausea (Patient refusal)
455 38 73.1 Grade 2 pain of skin (Herpes zoster)
505 37 71.2 Grade 2 interstitial pneumonia
682 36 69.2 Patient refusal
\